I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| CD8-positive, alpha-beta T cell | 27 studies | 50% ± 24% | |
| T cell | 19 studies | 33% ± 14% | |
| natural killer cell | 17 studies | 41% ± 20% | |
| mucosal invariant T cell | 16 studies | 68% ± 21% | |
| CD16-negative, CD56-bright natural killer cell, human | 15 studies | 56% ± 21% | |
| gamma-delta T cell | 12 studies | 32% ± 11% | |
| mature NK T cell | 12 studies | 40% ± 21% | |
| effector memory CD8-positive, alpha-beta T cell | 9 studies | 59% ± 23% | |
| CD8-positive, alpha-beta memory T cell | 9 studies | 47% ± 24% | |
| effector CD8-positive, alpha-beta T cell | 8 studies | 45% ± 24% | |
| CD4-positive, alpha-beta T cell | 7 studies | 25% ± 5% | |
| exhausted T cell | 5 studies | 78% ± 29% | |
| central memory CD8-positive, alpha-beta T cell | 4 studies | 45% ± 11% | |
| naive thymus-derived CD8-positive, alpha-beta T cell | 4 studies | 43% ± 13% | |
| double negative thymocyte | 4 studies | 55% ± 28% | |
| innate lymphoid cell | 4 studies | 55% ± 8% | |
| effector memory CD8-positive, alpha-beta T cell, terminally differentiated | 4 studies | 24% ± 6% | |
| effector CD4-positive, alpha-beta T cell | 3 studies | 28% ± 6% |
